Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

AustriaBack to Austria

Clinical trials in Vienna – page 17

841 clinical trials in Vienna, Austria across 10 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Vienna at a glance
841
clinical trials
  • Research sites10
Type of trial
Recruitment status
Quick filters

841 trials in Vienna

Open in trial search

Age-related macular degeneration

Recruiting

Study on Treating Neovascular Age-Related Macular Degeneration with Aflibercept, Ranibizumab, and Brolucizumab for Patients with Active Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Medical University Of Vienna

Acute myeloid leukaemia

Recruiting

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Dry age-related macular degeneration+1

Recruiting

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Porto-sinusoidal vascular disorder

Recruiting

Study on the Safety of Edoxaban for Patients with Porto-Sinusoidal Vascular Disorder

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Edoxaban
  • Sponsor:Medical University Of Vienna

Type IIa hyperlipidaemia

Recruiting

Study on the Safety and Effectiveness of Inclisiran in Children Aged 2 to Under 12 with Homozygous Familial Hypercholesterolemia

Registered drug
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Hepatocellular carcinoma+1

Recruiting

Study of drug combinations including cisplatin, carboplatin, doxorubicin, fluorouracil, vincristine, etoposide, irinotecan, gemcitabine, oxaliplatin and sorafenib for children with hepatoblastoma or hepatocellular carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:The University Of Birmingham

Asthma+1

Recruiting

Study of tezepelumab effects on airway barrier function in patients with severe asthma, with or without chronic rhinosinusitis with nasal polyps

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Tezepelumab
  • Sponsor:Medical University Of Vienna

Schizoaffective disorder depressive type+1

Recruiting

Study on Esketamine and Diphenhydramine for Treating Depression and Negative Symptoms in Schizophrenia Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years
  • Substances:Diphenhydramine Hydrochloride
  • Sponsor:Medical University Of Vienna

Anal incontinence

Recruiting

Study on ICEF15 for Treating Fecal Incontinence in Patients with Anal Sphincter Dysfunction

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:ICEF15
  • Sponsor:Innovacell GmbH

Intensive care

Recruiting

Evaluation of enoxaparin, dalteparin, nadroparin, tinzaparin and human albumin in adults admitted to intensive care unit with acute critical illness

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Dalteparin Sodium
  • Sponsor:Rigshospitalet

Hereditary angioedema

Recruiting

Study of deucrictibant tablets for prevention of hereditary angioedema attacks in adults and adolescents

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Deucrictibant
  • Sponsor:Pharvaris Netherlands B.V.

Prostate cancer

Recruiting

Study of [177Lu]Lu-PSMA-I&T Therapy for Patients with Oligometastatic Prostate Cancer Using Gozetotide and Stannous Oxide Combination

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Gozetotide
  • Sponsor:Medical University Of Vienna

Other cities in Austria

The busiest research cities in the country

All 47 cities in Austria

Clinical research in Vienna

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on innovative treatments for various cancer types, including pancreatic ductal adenocarcinoma, gastric cancer, and non-small cell lung cancer. Studies evaluating new therapeutic approaches for breast cancer and multiple myeloma are also underway.

  • Advanced Cancer Therapies
  • Targeted Treatment Approaches
  • Immunotherapy Studies

Research includes evaluation of novel drug combinations and immunotherapy approaches for improved patient outcomes.

02 Neuropsychiatric Studies

Investigations into major depression and its treatment mechanisms, including studies on dopamine synthesis and antidepressant effectiveness. Research examines innovative therapeutic approaches using ketamine and other compounds.

  • Depression Treatment
  • Neuroimaging Research
  • Therapeutic Mechanisms

Focus on understanding brain activation patterns and treatment responses in psychiatric conditions.

03 Autoimmune and Inflammatory Conditions

Research on plaque psoriasis, rheumatic diseases, and Sjögren's syndrome. Studies evaluate new biological therapies and treatment approaches for chronic inflammatory conditions.

  • Novel Therapeutic Agents
  • Disease Modification
  • Long-term Treatment Outcomes

Emphasis on developing targeted therapies for improved disease management and patient quality of life.

Back to AustriaAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.